Verapamil
- Generic Name
- Verapamil
- Brand Names
- Calan, Isoptin, Tarka, Verelan
- Drug Type
- Small Molecule
- Chemical Formula
- C27H38N2O4
- CAS Number
- 52-53-9
- Unique Ingredient Identifier
- CJ0O37KU29
- Background
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like diltiazem and flunarizine, bu...
- Indication
Verapamil is indicated in the treatment of vasopastic (i.e. Prinzmetal's) angina, unstable angina, and chronic stable angina. It is also indicated to treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter....
- Associated Conditions
- Chronic Stable Angina Pectoris, Cluster Headache, Heart Rate, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Supra-ventricular Tachyarrhythmias, Unstable Angina Pectoris, Vasospastic Angina
- Associated Therapies
- -
Bioequivalence Study Of Verapamil
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00668967
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Discrimination in Methadone-Maintained Humans Study 1
- Conditions
- Interventions
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 40
- Registration Number
- NCT00593463
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Pharmacotherapy of Treatment-Resistant Mania
- Conditions
- Interventions
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 45
- Registration Number
- NCT00518947
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Therapy With Verapamil or Carvedilol in Chronic Heart Failure
- Conditions
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 100
- Registration Number
- NCT00374465
- Locations
- 🇵🇱
Silesian Centre for Heart Disease, 3rd Department of Cardiology, Zabrze, Szpitalna 2 st., Poland
Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
- Conditions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2006-10-18
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 120
- Registration Number
- NCT00348530
- Locations
- 🇵🇱
Silesian Center for Heart Disease, IIIrd Department of Cardiology, Silesian Medical University, Zabrze, Poland
RATe Control in Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Asker & Baerum Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT00313157
- Locations
- 🇳🇴
Vestre Viken Hospital Trust, Baerum Hospital, Rud, Akershus, Norway
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
- Conditions
- Interventions
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1204
- Registration Number
- NCT00235014
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.